Basic Information
-
Targeting strategy
-
Gene targeting strategy for B-hCD37 MC38 cells. The CDS of human CD37 was inserted to replace part of murine exon 3 and exons 4-7. The insertion disrupts the endogenous murine CD37 gene, resulting in a non-functional transcript.
-
Protein expression analysis
-
CD37 expression analysis in B-hCD37 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD37 MC38 cultures were stained with species-specific anti-CD37 antibody. Human CD37 was detected on the surface of B-hCD37 MC38 cells but not wild-type MC38 cells. The 1-D11 clone of B-hCD37 MC38 cells was used for in vivo experiments.
-
Tumor growth curve & Body weight changes
-
Subcutaneous homograft tumor growth of B-hCD37 MC38 cells. B-hCD37 MC38 cells (5×105) and wild-type MC38 cells (5×105) were subcutaneously implanted into C57BL/6 mice (female, 6-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCD37 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.
-
Tumor volume and weight measurements
-
-
Protein expression analysis of tumor cells
-
B-hCD37 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=6), and on 31 days post inoculation, tumor cells were harvested and assessed for human CD37 expression by flow cytometry. As shown, human CD37 was highly expressed on the surface of tumor cells. Therefore, B-hCD37 MC38 cells can be used for in vivo efficacy studies of novel CD37 therapeutics.
